Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

Investments

1

About Yan Huang

Yan Huang is the president of Kangmeiteng Technology.

Yan Huang Headquarter Location

Beijing,

China

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Yan Huang News

LncRNA TDRG1 Promotes Proliferation, Invasion and Epithelial-Mesenchymal Transformation of Osteosarcoma Through PI3K/AKT Signal Pathway

Jun 14, 2020

Yan Huang,1 Yong-Qiang Xu,2 Si-Yin Feng,2 Xiang Zhang,2 Jiang-Dong Ni1 1Department of Orthopaedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province, People’s Republic of China; 2Department of Orthopaedics, Hunan Provincial People’s Hospital, Changsha, Hunan Province, People’s Republic of China Correspondence: Jiang-Dong Ni Department of Orthopaedics, The Second Xiangya Hospital of Central South University, No. 139, Renmin Middle Road, Furong District, Changsha, Hunan Province, People’s Republic of China Tel +86-73185295999 Email nijiangdong001@csu.edu.cn Objective: This study aimed to investigate the effect of long non-coding TDRG1 on proliferation and migration of osteosarcoma cells through PI3K/AKT signaling pathway. Materials and Methods: Altogether 87 cases of osteosarcoma tissues and adjacent tissues were collected, and osteosarcoma cells and osteoblasts were purchased. The expression of LncRNA TDRG1 in tissues and cells was detected by RT-PCR. Si-NC, si-TDRG1, and Sh-TDRG1 were transfected into osteosarcoma cells. L740Y-P (activator of PI3K/AKT pathway) and LY294002 (inhibitor of PI3k/AKT pathway) were used to interfere with PI3k/Akt signaling pathway in osteosarcoma cells. qRT-PCR was used to detect the expression of TDRG1 in osteosarcoma tissues and cells. WB was used to detect the expression of p-PI3K, p-AKT, N-cadherin, E-Cadherin, vimentin, Bax, Caspase-3, and Bcl-2 in cells. CCK-8, Transwell and cell scratch tests were used to detect cell proliferation, invasion and migration, and flow cytometry was used to detect cell apoptosis. Results: TDRG1 was highly expressed in osteosarcoma, and the levels of p-PI3K and p-AKT were also up-regulated. Cell experiments showed that inhibiting the expression of TDRG1 could inhibit the proliferation, invasion, migration and EMT of osteosarcoma cells, promote the apoptosis of cells, and up-regulating the expression of TDRG1 could promote the proliferation, invasion, migration and EMT of osteosarcoma cells and inhibit the apoptosis of cells. The 740Y-P intervention could reverse the inhibition of Si-TDRG1 on osteosarcoma cell proliferation, invasion, migration and EMT and the promotion of cell apoptosis. LY294002 intervention could reverse the promotion of Sh-TDRG1 on osteosarcoma cell proliferation, invasion, migration and EMT and the inhibition of cell apoptosis. Conclusion: TDRG1 is highly expressed in osteosarcoma tissue. Silencing the expression of osteosarcoma can inhibit the proliferation, invasion, migration and EMT of osteosarcoma cells by inhibiting PI3K/AKT signaling pathway, which may be a new target for diagnosis and treatment of osteosarcoma. Keywords: LncRNA TDRG1, PI3K/AKT, osteosarcoma cells, proliferation, migration This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License . By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms .

Yan Huang Investments

1 Investments

Yan Huang has made 1 investments. Their latest investment was in Meiteng Youfang as part of their Seed on March 3, 2020.

CBI Logo

Yan Huang Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/13/2020

Seed

Meiteng Youfang

$1.14M

Yes

3

Date

3/13/2020

Round

Seed

Company

Meiteng Youfang

Amount

$1.14M

New?

Yes

Co-Investors

Sources

3

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.